Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

Purpose Ixazomib is an investigational proteasome inhibitor with demonstrated antitumor activity in xenograft models of multiple myeloma (MM), lymphoma, and solid tumors. This open-label, phase 1 study investigated intravenous (IV) ixazomib, in adult patients with advanced non-hematologic malignanci...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, David C., Kalebic, Thea, Infante, Jeffrey R., Siu, Lillian L., Sullivan, Daniel, Vlahovic, Gordana, Kauh, John S., Gao, Feng, Berger, Allison J., Tirrell, Stephen, Gupta, Neeraj, Di Bacco, Alessandra, Berg, Deborah, Liu, Guohui, Lin, Jianchang, Hui, Ai-Min, Thompson, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435632/
https://www.ncbi.nlm.nih.gov/pubmed/25777468
http://dx.doi.org/10.1007/s10637-015-0230-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435632/
https://www.ncbi.nlm.nih.gov/pubmed/25777468
http://dx.doi.org/10.1007/s10637-015-0230-x

Ejemplares similares